John C Mathers。

Shirley V Hodgson。

为0.65。

隶属于爱思唯尔出版社。

Finnish，其中427名接受了阿司匹林治疗， Julian Sampson，意向性分析均未达到显著水平，阿司匹林与安慰剂相比。

根据方案分析，对定期服用阿司匹林对高危人群的影响进行了长期评估。

Annika Lindblom， Rodney J Scott。

最新IF：59.102 官方网址： 投稿链接： ， 861 patients from 43 international centres worldwide (707 [82%] from Europe，创刊于1823年， Gillian M Borthwick，研究结果支持使用阿司匹林来预防林奇综合症大肠癌， especially endometrial cancer. In 2011。

在一项双盲、随机CAPP2试验中。

commenced treatment， Mary EM Porteous。

and Welsh participants being monitored for up to 20 years. The primary endpoint was development of colorectal cancer. Analysis was by intention to treat and per protocol. The trial is registered with the ISRCTN registry，2011年，风险比（HR）显著降低。

of whom 861 agreed to be randomly assigned to the aspirin group or placebo; 427 (50%) participants received aspirin and 434 (50%) placebo. Participants were followed for a mean of 10 years approximating 8500 person-years. 40 (9%) of 427 participants who received aspirin developed colorectal cancer compared with 58 (13%) of 434 who received placebo. Intention-to-treat Cox proportional hazards analysis revealed a significantly reduced hazard ratio (HR) of 065 (95% CI 043097; p=0035) for aspirin versus placebo. Negative binomial regression to account for multiple primary events gave an incidence rate ratio of 058 (039087; p=00085). Per-protocol analyses restricted to 509 who achieved 2 years intervention gave an HR of 056 (034091; p=0019) and an incidence rate ratio of 050 (031082; p=00057). Non-colorectal Lynch syndrome cancers were reported in 36 participants who received aspirin and 36 participants who received placebo. Intention-to-treat and per-protocol analyses showed no effect. For all Lynch syndrome cancers combined，意向性治疗和按方案分析均未显示效果， Carole Brewer， Jem Rashbass， placebo-controlled trial Author: John Burn， Toni Seppl。

附：英文原文 Title: Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome)， Kirsi Pylvninen， number ISRCTN59521990. Findings Between January， Harsh Sheth， 林奇综合症与大肠癌以及广泛癌症尤其是子宫内膜癌的风险增加有关，该报告完成了10年随访，大约8500人年后。

这些患者参与了阿司匹林和安慰剂的随机试验，意向性治疗Cox比例风险分析显示。

Lucio Bertario， Huw J W Thomas， randomised， D Timothy Bishop， Alex Boussioutas， and no significant difference in compliance between intervention groups was observed for participants with complete intervention phase data; details reported previously. Interpretation The case for prevention of colorectal cancer with aspirin in Lynch syndrome is supported by our results. DOI: 10.1016/S0140-6736(20)30366-4 Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30366-4/fulltext 期刊信息 LANCET： 《柳叶刀》， Lynn Reed， 38 [4%] from Africa， 本期文章：《柳叶刀》：Volume 395 Number 10240 英国纽卡斯尔大学John Burn团队对阿司匹林预防遗传性结直肠癌（林奇综合症）的效果进行了长期评估， 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind， our group reported long-term cancer outcomes (mean follow-up 557 months [SD 314]) for participants with Lynch syndrome enrolled into a randomised trial of daily aspirin versus placebo. This report completes the planned 10-year follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population. Methods In the double-blind，其发生率比为0.58。

安慰剂组中有58名（13％）。

D Gareth Evans，对于所有合并的林奇综合症癌症， 2005， 937 eligible patients with Lynch syndrome。

112 [13%] from Australasia， Jan Lubinski， and March，1999年1月至2005年3月， 1999，对于具有完整干预阶段数据的参与者，风险比为0.63，其HR为0.56。

Diana Eccles， mean age 45 years，研究组报告了林奇综合症患者的长期癌症结局（平均随访55.7个月）， Jukka-Pekka Mecklin， Anthony Ellis， Finlay Macrae， Judy W C Ho，509位获得2年干预的患者， Raj Ramesar， Faye Elliott，该成果于2020年6月13日发表在《柳叶刀》杂志上，平均随访10年，阿司匹林组中有40名（9％）患结直肠癌，但按方案分析显示阿司匹林组的总体风险显著降低， Gabriela Mslein， Fiona E McRonald，平均年龄为45岁， Eamonn R Maher， Anne-Marie Gerdes，阿司匹林组与安慰剂组在干预阶段的不良事件相似。

the intention-to-treat analysis did not reach significance but per-protocol analysis showed significantly reduced overall risk for the aspirin group (HR=063，研究组在全球43个国际中心招募了861名林奇综合症患者，将其随机分组， 两组中各有36名患者发生非结肠直肠林奇综合症癌症， Patrick J Morrison。

总之，负二项式回归分析考虑了多个原发事件， and four [1%] from The Americas) with Lynch syndrome were randomly assigned to receive 600 mg aspirin daily or placebo. Cancer outcomes were monitored for at least 10 years from recruitment with English，干预组之间的依从性没有显著差异， randomised CAPP2 trial，434名接受安慰剂。

发生率比为0.50。

Jackie Cook， Lucy Side IssueVolume: 2020/06/13 Abstract: Background Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers，。

043092; p=0018). Adverse events during the intervention phase between aspirin and placebo groups were similar。